Although there is no clinical trial to induce ferroptosis by targeting TGF-β1/Smad pathway for GC therapy, activation of TGF-β1-induced ferroptosis could attenuate the development of hepatoma [73]. Here, TGFB1 is linked to hepatocellular carcinoma.